# OPTIMISMM (NCT01734928)

> Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01734928
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: Pomalidomide; Bortezomib; Dexamethasone
- Enrollment: 559
- Primary outcome: Progression Free Survival by Independent Response Adjudication Committee (IRAC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 16
- Podcasts: 2
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=optimismm-nct01734928

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01734928", "email": "<work email>"}; the inbox owner confirms by the emailed link.